Corbion
Corbion announces strong full-year results with sales growth, +25% Adjusted EBITDA improvement, and strong FCF; proposes +5% dividend increase
Corbion announces strong full-year results with sales growth, +25% Adjusted EBITDA improvement, and strong FCF; proposes +5% dividend increase
Corbion, the Amsterdam-listed sustainable ingredients company that champions preservation through application of science, today publishes its results for the year ending 31 December 2024.
Key highlights annual results 2024:
- Organic sales growth: +2.2% (Q4: +1.3%)
- Volume/mix: +5.2% (Q4: +2.9%)
- Price: -3.0% (Q4: -1.6%)
- Continued Operations:
- Sales: € 1,288.1 million (Q4: € 315.2 million)
- Adjusted EBITDA: € 175.0 million (Q4: € 39.3 million)
- Operating profit: € 77.3 million (Q4: € 15.2 million)
- Free Cash Flow: € 350.1 million, € 98.3 million when excluding divestment proceeds
- Cash flow from operating activities increased € 18.7 million to € 184.1 million
- Adjusted EBITDA organic growth of +23.3%
- Covenant net debt/covenant EBITDA improved to 2.1x at year-end (year-end 2023: 3.1x)
- World-leading lactic acid plant in Thailand started up
- Divestment of Emulsifiers business completed
- Proposal to increase dividend by 5% to € 0.64 per share
Outlook FY 2025:
- Volume/mix growth: 2-6%
- Adjusted EBITDA organic growth: >25%
- Free Cash Flow: >€ 85 million
€ million* | FY 2024 | FY 2023 | FY growth | FY Organic growth | Q4 2024 | Q4 2023 | Q4 growth | Q4 Organic growth | |
Sales | 1,288.1 | 1,264.1 | +1.9% | +2.2% | 315.2 | 311.8 | +1.1% | +1.3% | |
Adjusted EBITDA | 175.0 | 140.2 | +24.8% | +23.3% | 39.3 | 36.8 | +6.8% | +8.2% | |
Adjusted EBITDA margin (%) | 13.6% | 11.1% | 12.5% | 11.8% | |||||
Operating profit | 77.3 | 77.3 | 0.0% | -4.4% | 15.2 | 33.4 | -54.5 % | -55.0% |
*Continued operations
Commenting on today’s results, Olivier Rigaud, CEO, stated: “I am pleased to share that in 2024, Corbion successfully met its upgraded targets for sales and Adjusted EBITDA, while significantly surpassing our free cash flow target. We achieved organic sales growth and double-digit increases in both Adjusted EBITDA and Adjusted Operating Profit. Our strong volume/mix performance, our focus on operational efficiencies, the successful implementation of our restructuring program, and our capex discipline resulted in the significant increase in free cash flow. Following our strong performance improvement, and our confidence in the future, we are proposing a regular cash dividend increase of +5% to € 0.64 per ordinary share to be submitted for approval to the annual General Meeting of Shareholders.
In Functional Ingredients & Solutions, sales declined slightly as growth in volume/mix was offset by a decline in pricing. We achieved volume/mix growth in our Food business, including in our product/market adjacencies-- namely dairy stabilizers, natural antioxidants, natural mold inhibitors, and dough conditioners.
In Health & Nutrition, we continued to see strong double-digit growth in both volume/mix and price, particularly in the Nutrition business serving aquaculture and pet-food end markets. Our focus on high-margin products and expanding our product portfolio contributed significantly to this growth. Adjusted EBITDA grew by +84.1% for the full year, driven by the Nutrition business. In the fourth quarter, and as anticipated, we saw positive volume/mix growth, albeit at a lower level than the previous quarter on a strong phasing effect in Q3.”
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Zealand Pharma12.5.2025 07:00:00 CEST | Press release
Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025
Clariant International Ltd12.5.2025 07:00:00 CEST | Press release
Clariant rejects Dow Europe’s allegations against four companies related to the 2020 competition law infringement
Jeito Capital12.5.2025 07:00:00 CEST | Press release
Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal
Tecan Group AG12.5.2025 06:30:00 CEST | Press release
Q1 2025 Qualitative Update: Tecan reports performance in line with expectations and confirms outlook for full year 2025
Akero Therapeutics Inc.10.5.2025 16:00:00 CEST | Press release
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom